Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Mediwound (MDWD) Stock Price & Analysis

463 Followers

MDWD Stock Chart & Stats

$14.11$0.03(-0.98%)
At close: 4:00 PM EST
$12$13$14Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$13.97 - $14.41
52-Week Range
$11.80 - $19.70
Previous Close
$14.25
Volume
N/A
Average Volume (3M)
121.64K
Market Cap
$182.16M
Enterprise Value
$163.59M
Total Cash (Recent Filing)
$35.34M
Total Debt (Recent Filing)
$9.54M
Price to Earnings (P/E)
―
Beta
0.81
Next Earnings
Nov 12, 2026 (Est.)
EPS Estimate
-0.71
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

NexoBrid Commercial Adoption

Record quarterly performance and ordering by approximately 80 burn centers indicate growing clinical adoption through the U.S. partner channel. Broader utilization can support recurring product demand, strengthen NexoBrid’s commercial position, and improve the durability of future revenue growth.

Government-Backed Partnerships

The MSA links MediWound to a long-duration, government-backed program and creates potential development revenue beyond ordinary product sales. This partnership can broaden NexoBrid’s applications, validate the platform, and provide strategic support for future commercialization.

EscharEx Phase III Progress

Active late-stage enrollment advances EscharEx toward a potentially important regulatory and commercial milestone in chronic wound care. Progress across a broad international site network supports execution credibility and preserves the opportunity to expand MediWound beyond burn-treatment markets.

Bears Say

Persistent Cash Burn

The rapid decline in cash while operations and development programs remain loss-making weakens MediWound’s self-funding capacity. Continued burn could require additional financing before major commercial milestones, increasing capital-allocation pressure and limiting flexibility over the next several quarters.

Revenue And Margin Deterioration

Sharp revenue contraction combined with materially lower gross margins indicates weak near-term operating leverage and limited earnings support from the current commercial base. Unless program revenue and product demand recover, the decline can prolong losses and make sustained profitability more difficult.

Manufacturing Capacity Constraints

Regulatory-tied facility work delays access to expanded commercial capacity and limits the company’s ability to scale product sales in the near term. The extended timeline may constrain NexoBrid availability, defer growth from additional markets, and raise execution risk around future demand.

Mediwound News

MDWD FAQ

What was Mediwound’s price range in the past 12 months?
Mediwound lowest stock price was $11.80 and its highest was $19.70 in the past 12 months.
What is Mediwound’s market cap?
Mediwound’s market cap is $182.16M.
When is Mediwound’s upcoming earnings report date?
Mediwound’s next earnings report is estimated for Nov 12, 2026 (not yet confirmed), which is in 1 day.
How were Mediwound’s earnings last quarter?
Mediwound released its earnings results on Aug 13, 2026. The company reported -$0.77 earnings per share for the quarter, missing the consensus estimate of -$0.762 by -$0.008.
Is Mediwound overvalued?
According to Wall Street analysts Mediwound’s price is currently Undervalued.
Does Mediwound pay dividends?
Mediwound does not currently pay dividends.
What is Mediwound’s EPS estimate?
Mediwound’s EPS estimate is -0.71.
How many shares outstanding does Mediwound have?
Mediwound has 12,910,278 shares outstanding.
What happened to Mediwound’s price movement after its last earnings report?
Mediwound reported an EPS of -$0.77 in its last earnings report, missing expectations of -$0.762. Following the earnings report the stock price went down -2.732%.
Which hedge fund is a major shareholder of Mediwound?
Hedge funds hold Mediwound shares: the largest hedge-fund position in Mediwound is 71,885,836 shares, and hedge funds increased their holdings by 76.7K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology